ARTICLE | Company News
Avaxia Biologics, Courtagen Life Sciences deal
March 5, 2012 8:00 AM UTC
The companies partnered to develop an assay to evaluate the effect of Avaxia's AVX-470 in treating gastrointestinal damage following radiation exposure in preclinical models and in humans. The companies will use Courtagen's Avantra Q400 Protein Biomarker Technology, a multiplex immunoassay system. Details were not disclosed. ...